Deutsche still bullish on Gilead after Sovaldi launch

Deutsche Bank is out with some commentary on Gilead (GILD -0.6%) two weeks into the Sovaldi launch.

IMS data reportedly show 834 new patient starts as of the week ending December 20.

"Assuming new starts increasing to 1000/wk by end of the year and gross to net of 15%, we [calculate] Q4 sales at $61M. If new starts rise to 2000/wk by year end, assuming a gross to net of 15%, we [calculate] Q4 sales at $98M," analyst Robyn Karnauskas notes.

Buy rating maintained.

Price target is $95.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs